

FILE 'HOME' ENTERED AT 11:21:06 ON 26 JUL 2000

=> file medline, biosis, embase, caplus, uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 11:21:43 ON 26 JUL 2000

FILE 'BIOSIS' ENTERED AT 11:21:43 ON 26 JUL 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 11:21:43 ON 26 JUL 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 11:21:43 ON 26 JUL 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:21:43 ON 26 JUL 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (flt4 (s) ligand) (p) antibody
L1 5 (FLT4 (S) LIGAND) (P) ANTIBODY

```
=> dup rem l1  
  
PROCESSING COMPLETED FOR L1  
[REMOVED]
```

=> d.13 total_ibib_kwic

L2 ANSWER 1 OF 4 USPATFULL
ACCESSION NUMBER: 1999:110189 USPATFULL
TITLE: Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production
INVENTOR(S): Davis-Smyth, Terri Lynn, Foster City, CA, United States
States
Chen, Helen Hsifei, Daly City, CA, United States
Presta, Leonard, San Francisco, CA, United States
Ferrara, Napoleone, San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., S. San Francisco, CA, United States
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5952199	19990914
APPLICATION INFO.:	US 1997-874678	19970613 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-643839, filed on 7 May 1996	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Feisee, Lila	
ASSISTANT EXAMINER:	Kaufman, Claire M.	

LEGAL REPRESENTATIVE: Johnston, Sean; Vance, Dol A.Flehr Hohbach Test
Albritton & Herbert LLP

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 10 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 2658

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . expressing 293 cells were deprived of serum 16-18 hrs prior to stimulation by a given factor. Cells were stimulated with **FLT4 ligand** (VH1.4.5; VEGF-C/VRP) at a concentration of 400 ng/ml, 50 ng/ml VEGF, or 0.5 nM PLGF for 15 minutes at 37.degree.. . . 1 ml lysis buffer. The lysate was cleared of cellular debris and the receptors were immunoprecipitated using JTL.1, a polyclonal **antibody** directed against the extracellular domain of the **FLT4** receptor (see Lee et. al., Proc. Natl. Acad. Sci USA, 93:1988-1992 (1996)). The immunoprecipitates were then subjected to western gel/blot analysis using the 4G10 anti-phosphotyrosine monoclonal **antibody** (UBI, Lake Placid, N.Y.). Immunoreactive bands were visualized with an ABC kit according to manufacturers directions (Vector Laboratories).

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 1
ACCESSION NUMBER: 1998:471458 CAPLUS
DOCUMENT NUMBER: 129:119594
TITLE: Cloning and cDNA sequences of human **FLT4** receptor tyrosine kinase isoforms and stimulator ligand
INVENTOR(S): Alitalo, Kari; Aprelikova, Olga; Pajusola, Katri; Armstrong, Elina; Korhonen, Jaana; Kaipainen, Arja
PATENT ASSIGNEE(S): Helsinki University Licensing, Ltd., Finland
SOURCE: U.S., 65 pp. Cont.-in-part of U. S. Ser. No. 959,951, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5776755	A	19980707	US 1994-340011	19941114
WO 9833917	A1	19980806	WO 1998-US1973	19980202
W: AU, CA, CN, JP, NZ, US, US, US, US, US, US, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9862624	A1	19980825	AU 1998-62624	19980202
EP 972028	A1	20000119	EP 1998-904842	19980202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:				
US 1992-959951 19921009				
US 1994-340011 19941114				
US 1995-510133 19950801				
US 1996-585895 19960112				
US 1996-601132 19960214				
US 1996-671573 19960628				
WO 1996-FI427 19960801				
US 1997-795430 19970205				
WO 1998-US1973 19980202				

IT **Antibodies**

RL: ARG (Analytical reagent use); BPN (Biosynthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cloning and cDNA sequences of human **FLT4** receptor tyrosine kinase isoforms and stimulator ligand)

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1997:278962 CAPLUS
 DOCUMENT NUMBER: 126:247137
 TITLE: VRP: a protein tyrosine kinase Flt4 ligand related to
 vascular endothelial growth factor
 INVENTOR(S): Lee, James; Wood, William
 PATENT ASSIGNEE(S): Genentech, Inc., USA
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9709427	A1	19970313	WO 1996-US14075	19960830
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
AU 9670128	A1	19970327	AU 1996-70128	19960830
AU 710696	B2	19990930		
EP 848755	A1	19980624	EP 1996-931450	19960830
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11514976	T2	19991221	JP 1996-511317	19960830
PRIORITY APPLN. INFO.:			US 1995-3491	19950908
			WO 1996-US14075	19960830

IT Antibodies

Monoclonal antibodies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (to VRP; VRP: protein tyrosine kinase **Flt4 ligand**
 related to vascular endothelial growth factor)

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1997:240615 CAPLUS
 DOCUMENT NUMBER: 126:221078
 TITLE: A tyrosine phosphorylation-stimulating ligand,
 VEGF-C,
 for the FLT4 receptor tyrosine kinase and a cDNA
 encoding it
 INVENTOR(S): Alitalo, Kari; Joukov, Vladimir
 PATENT ASSIGNEE(S): Helsinki University Licensing Ltd. Oy, Finland;
 Alitalo, Kari; Joukov, Vladimir
 SOURCE: PCT Int. Appl., 183 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705250	A2	19970213	WO 1996-FI427	19960801
WO 9705250	A3	19970410		
W: AU, CA, CN, JP, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2228248	AA	19970213	CA 1996-2228248	19960801
AU 9666169	A1	19970226	AU 1996-66169	19960801
AU 711578	B2	19991014		
EP 842273	A2	19980520	EP 1996-925768	19960801

R: AT, [REDACTED], CH, DE, DK, ES, FR, GB, GR, [REDACTED] LI, LU, NL, SE, MC, PT,
 IE,
 JP 11510689 T2 19990921 JP 1996-507262 19960801
 CN 1242043 A 20000119 CN 1996-197353 19960801
 WO 9833917 A1 19980806 WO 1998-US1973 19980202
 W: AU, CA, CN, JP, NZ, US, US, US, US, US, US
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
 SE
 AU 9862624 A1 19980825 AU 1998-62624 19980202
 EP 972028 A1 20000119 EP 1998-904842 19980202
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 PRIORITY APPLN. INFO.: US 1995-510133 19950801
 US 1996-585895 19960112
 US 1996-601132 19960214
 US 1996-671573 19960628
 US 1994-340011 19941114
 WO 1996-FI427 19960801
 US 1997-795430 19970205
 WO 1998-US1973 19980202

IT **Antibodies**

Monoclonal antibodies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (to **FLT4 ligand** VEGF-C; tyrosine
 phosphorylation-stimulating ligand, VEGF-C, for **FLT4**
 receptor tyrosine kinase and cDNA encoding it)

=> d his

(FILE 'HOME' ENTERED AT 11:21:06 ON 26 JUL 2000)

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, USPATFULL' ENTERED AT 11:21:43 ON
 26 JUL 2000

L1 5 S (FLT4 (S) LIGAND) (P) ANTIBODY
 L2 4 DUP REM L1 (1 DUPLICATE REMOVED)

=> s (flt4 (s) ligand) (p) cancer

L3 0 (FLT4 (S) LIGAND) (P) CANCER

=> s flt4 (s) inhibitor

L4 5 FLT4 (S) INHIBITOR

=> dup rem

ENTER L# LIST OR (END):14

PROCESSING COMPLETED FOR L4

L5 5 DUP REM L4 (0 DUPLICATES REMOVED)

=> d 15 total ibib kwic

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 2000:260057 CAPLUS
 DOCUMENT NUMBER: 132:298824
 TITLE: Flt4 (VEGFR-3) as a target for tumor imaging and
 anti-tumor therapy
 INVENTOR(S): Alitalo, Kari; Kaipainen, Arja; Valltola, Reija;
 Jussila, Lotta
 PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, USA; Helsinki
 University Licensing Ltd. Oy
 SOURCE: PCT Int. Appl., 148 pp.

DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 20000021560	A1	20000420	WO 1999-US23525	19991008
W: AU, CA, CN, JP, NO, NZ				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1998-169079	19981009
REFERENCE COUNT:	3			
REFERENCE(S):	(1) Alitalo, K; WO 9533772 A 1995 (2) Helsinki University Licensing; WO 9705250 A 1997 (3) Joukov, V; THE EMBO JOURNAL 1996, V15(2), P290 CAPLUS			

IT Mammary gland
(carcinoma, **inhibitors**; **Flt4** (VEGFR-3) as a target
for tumor imaging and anti-tumor therapy)

L5 ANSWER 2 OF 5 USPATFULL
ACCESSION NUMBER: 2000:18280 USPATFULL
TITLE: Nucleic acid sequence of senescence associated gene
INVENTOR(S): Funk, Walter, Hayward, CA, United States
PATENT ASSIGNEE(S): Geron Corporation, Menlo Park, CA, United States (U.S. corporation)

PATENT INFORMATION:	NUMBER	DATE
APPLICATION INFO.:	US 6025194	20000215
DOCUMENT TYPE:	US 1997-974180	19971119 (8)
PRIMARY EXAMINER:	Utility	
ASSISTANT EXAMINER:	Huff, Sheela	
LEGAL REPRESENTATIVE:	Bansal, Geetha P.	
NUMBER OF CLAIMS:	Earp, David J.; Kaster, Kevin 10	
EXEMPLARY CLAIM:	1, 6	
LINE COUNT:	4667	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
DETD	. . . cyclin B1	
H41433	302484 protein kinase C zeta	
W38932	304843 heme oxygenase 2	
W38689	305014 ornithine decarboxylase	
W39150	305149 IAP (inhibitor of apoptosis)	
N91919	306848 mineralocorticoid receptor	
W24300	306951 retinol-binding protein I, cellular	
N95176	307293 rap-1A (ras related protein)	
N92931	307710. . . sapiens 5,10-methenyltetrahydrofolate synthetase AA033966 429883 cytochrome P450 IIC8	
AA034057	429925 a-1 acid glycoprotein	
AA034051	429926 APC	
AA033993	429934 DNA-binding protein inhibitor ID-2	
T91369	116501 flk-1/KDR (VEGF receptor 2)	
AA034015	430006 dermatopontin	
AA026197	469275 prostaglandin-I synthase (prostacyclin synthase) AA027039 469378 TNF initial. . . AA044619 486757 cathepsin K	
AA043226	486785 plasminogen	
AA045303	487092 interferon-inducible protein 1-8D	
AA043718	487341 endothelin receptor	
AA046659	487394 plasminogen activator inhibitor -1 (PAI-1)	
AA046720	487416 IGF Binding Protein 4	
AA044993	487513 connective tissue growth factor precursor	
AA045364	487811 peptidyl-glycine alpha-amidating monooxygenase (PAM)	
. . . 488891	ubiquitin-conjugating enzyme E2-17KD (RAD6-B)	

AA047379 488932 importin-beta
AA046892 488974 defender against cell death 1
AA047092 488999 protein kinase C inhibitor
AA047161 489042 CD30
AA057189 489055 RhoG
AA058523 489327 Human mRNA for raf oncogene
AA058472 489366 IGF binding protein 1
AA101829 . . . AA293368 726153 Ku (70kDa subunit)
AA397905 726506 Thrombin receptor
AA394212 726536 tristetraproline (zinc-finger transcriptional regulator)
AA398273 726722 tyrosine-protein kinase receptor **FLT4** (VEGF3
receptor)
AA398424 726898 reticulin
AA435903 728710 COUP transcription factor (V-erbA related ear-3
protein)
AA398782 729256 cap-binding protein eIF-4E
AA421225 . . . FHF4
AA400276 742657 heparin-binding EGF-like growth factor
AA411316 755032 MAD2
AA423811 755456 IGF binding protein 2
AA496426 755832 placental ribonuclease/angiogenin **inhibitor**
AA496611 755964 natriuretic peptide receptor
AA482111 756377 collagenase **inhibitor**
AA429058 756936 monoamine oxidase
AA496096 757144 Activin B-C chain
AA442853 757873 P35 regulatory subunit of CDK5
AA393689 758424 AKT (rac. . .)

L5 ANSWER 3 OF 5 USPATFULL

ACCESSION NUMBER: 1999:155460 USPATFULL
TITLE: Methods of assaying differential expression
INVENTOR(S): Chenchik, Alex, Palo Alto, CA, United States
Jokhadze, George, Mountain View, CA, United States
Bibilashvilli, Robert, Moscow, Russian Federation
PATENT ASSIGNEE(S): Clontech Laboratories, Inc., Palo Alto, CA, United
States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5994076	19991130
APPLICATION INFO.:	US 1997-859998	19970521 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fredman, Jeffrey	
LEGAL REPRESENTATIVE:	Bozicevic & Reed LLP; Field, Bret E.	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	13450	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
DETD		NO.144
	CCCTGTAAACATGAGAATGGGCTCGTGACA	30

TYROSINE KINASE, RECEPTOR TIE
SEQ ID NO.145

CTACAGTGTCTATACCAAGAGTGATGTC
31

- SEQ ID NO.146 GGCTGTAAGGGTCAGACTGGTCACAGGTTA 30

TYROSINE KINASE, RECEPTOR **FLT4**, CLASS III
SEQ ID NO.147

CAGGTGCTTCCCAGACACTGGCGTTACT

28

- SEQ ID NO.148 ACTCATATTACCAAGGAATAACTGGCGGGCA 31

HELIX-LOOP-HELIX PROTEIN 1R21
SEQ ID NO.149

HAEs-1

SEQ ID NO.203

GACTCCTGCGACCGCATCAAAGACGAATT

30

- SEQ ID NO.204

GCTGTCGGATGATAGAGTTCAGCTCGGGA 29

DNA-BINDING PROTEIN/PLASMINOGEN ACTIVATOR INHIBITOR-1 REGULATOR
SEQ ID NO.205

CCTCTTGTCACTCCACTCAGCGCCATGT

28

- SEQ ID NO.206

CTCCCGTGTAAATAGCGTAGTCCAACCACAT 30

INTERFERON, GAMMA RECEPTOR

SEQ ID NO.207

ACGTTCCACAGGGCCAGGTGAGCTTCT

28

- SEQ. . .

L5 ANSWER 4 OF 5 USPATFULL

ACCESSION NUMBER: 1998:79002 USPATFULL

TITLE: FLT4, a receptor tyrosine kinase

INVENTOR(S): Alitalo, Kari, Espoo, Finland

Aprelikova, Olga, Helsinki, Finland

Pajusola, Katri, Helsinki, Finland

Armstrong, Elina, Helsinki, Finland

Korhonen, Jaana, Helsinki, Finland

Kaipainen, Arja, Helsinki, Finland

PATENT ASSIGNEE(S): Helsinki University Licensing, Ltd., Helsinki, Finland
(non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5776755 19980707

APPLICATION INFO.: US 1994-340011 19941114 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-959951, filed
on 9 Oct 1992, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Patterson, Jr., Charles L.

ASSISTANT EXAMINER: Moore, William W.

LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun

NUMBER OF CLAIMS: 45

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 32 Drawing Figure(s); 23 Drawing Page(s)

LINE COUNT: 2570

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The present invention also provides a cell line source for the ligand
of

the **FLT4** receptor tyrosine kinase. Using the conditioned
medium from these cells the **FLT4** ligand may be purified and
cloned by using methods standard in the art. Using this conditioned
medium an assay system for **FLT4** ligand and dimerization

inhibitors as well as **inhibitors** of **FLT4**
signal transduction are obtained, which allow for identification and
preparation of such **inhibitors**.

SUMM The identification of **FLT4** stimulating ligand makes it
directly possible to assay for **inhibitors** of this ligand or
inhibitors of **FLT4** function. Such **inhibitors**
are simply added to the conditioned media containing the **FLT4**
ligand and if they inhibit autophosphorylation, they act as **FLT4**
signalling **inhibitors**. For example, synthetic peptides may be
assayed for inhibition of **FLT4**-ligand interaction or
FLT4 dimerization. Such putative **inhibitors** of

FLT4 and, in addition, antibodies against the **FLT4** ligand, peptides or other compounds blocking **FLT4** receptor-ligand interaction, as well as antisense oligonucleotides complementary to the sequence of mRNA encoding the **FLT4** ligand are useful in the regulation of endothelial cells and in the treatment of diseases associated with endothelial cell function.

DETD The polyclonal antibodies against the **FLT4** C-terminus have been described in Pajusola et al., of record. For immunoprecipitation, the supernatants were incubated for 2 hours on ice with 2 to 4 ml of rabbit polyclonal anti-**FLT4** antiserum. About 30 ml of a 50% (vol/vol) solution of protein A-Sepharose (Pharmacia) in PBS was added and incubation was. . . at 50.degree. C. in 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7 with occasional agitation and restained with anti-**FLT4** antibodies (1:1000 dilution) followed by staining with peroxidase-conjugated swine anti-rabbit antibodies (1:1000 dilution, Dako, P217). As a positive control for the tyrosine phosphorylation of **FLT4**, anti-**FLT4** immunoprecipitates from the **FLT4** expressing NIH3T3 cells treated with 100 mM of the tyrosyl phosphatase **inhibitor** sodium pervanadate (PerVO₄) for 20 minutes were used. Treatment of cells with Sodium pervanadate was done by addition of 100. . . CO.sub.2. That procedure resulted in the generation of the peroxidized form of vanadate (vanadyl hydroperoxide), which is a very potent **inhibitor** of the protein tyrosine phosphatases in living cells.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1997:776257 CAPLUS

DOCUMENT NUMBER: 128:47303

TITLE: Chimeric forms of vascular endothelial growth factor receptor proteins as novel inhibitors of vascular endothelial growth factor activity

INVENTOR(S): Davis-Smyth, Terri Lynn; Chen, Helen Hsifei; Presta, Leonard; Ferrara, Napoleone

PATENT ASSIGNEE(S): Genentech, Inc., USA; Davis-Smyth, Terri Lynn; Chen, Helen Hsifei; Presta, Leonard; Ferrara, Napoleone

SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9744453	A1	19971127	WO 1997-US7694	19970506
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9730604	A1	19971209	AU 1997-30604	19970506
AU 717112	B2	20000316		
EP 907733	A1	19990414	EP 1997-925475	19970506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000502357	T2	20000229	JP 1997-542429	19970506
US 5952199	A	19990914	US 1997-874678	19970613
PRIORITY APPLN. INFO.:			US 1996-643839	19960507
			WO 1997-US7694	19970506

IT Proteins (specific proteins and subclasses)

RL: BAC (Biological activity or effector, except adverse); BPN
(Biosynthetic preparation); BIOL (Biological ~~body~~); PREP (Preparation)
(gene **FLT4**, fusion products with Ig-like ligand-binding
domains of VEGF receptors; chimeric forms of vascular endothelial
growth factor receptor proteins as novel **inhibitors** of
vascular endothelial growth factor activity)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.74	23.89

STN INTERNATIONAL LOGOFF AT 11:26:03 ON 26 JUL 2000

09313299 results

SEQ ID NO: 3 amino acids 21-49

RESULT 9
Y22320
ID Y22320 standard; Protein; 419 AA.
XX
AC Y22320;
XX
DT 22-SEP-1999 (first entry)
XX
DE Full length human VEGF2 protein sequence.
XX
KW VEGF2; vascular endothelial growth factor 2; angiogenesis; bone damage;
KW endothelial cell proliferation; tissue damage; therapy.
XX
OS Homo sapiens.
XX
PN US5932540-A.
XX
PD 03-AUG-1999.
XX
PF 24-DEC-1997; 97US-0999811.
XX
PR 24-DEC-1997; 97US-0999811.
PR 08-MAR-1994; 94US-0207550.
PR 06-JUN-1995; 95US-0465968.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Cao L, Hu J, Rosen CA;
XX
DR WPI; 1999-443606/37.
DR N-PSDB; X84837.
XX
PT Vascular endothelial growth factor 2 for wound healing and vascular
repair
XX
PS Claim 1; Fig 1; 49pp; English.
XX
CC This sequence is the vascular endothelial growth factor 2 (VEGF2),
CC of the invention. The isolated polypeptide is useful for stimulating
CC angiogenesis, by promoting the proliferation of endothelial cells, for
CC the treatment of a wound, or for the treatment of tissue or bone damage.
XX
SQ Sequence 419 AA;

Query Match 100.0%; Score 145; DB 20; Length 419;
Best Local Similarity 100.0%; Pred. No. 1.2e-13;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEAT 29
Db 21 gpreapaaaaafesglrlsdaepdageat 49

RESULT 2
US-09-042-105-2
; Sequence 2, Application US/09042105
; Patent No. 6040157
; GENERAL INFORMATION:
; APPLICANT: HU, JING-SHAN
; APPLICANT: ROSEN, CRAIG A.
; APPLICANT: CAO, LIANG

TITLE OF INVENTION: VASCULAR ENDOTHELIAL GROWTH FACTOR 2
NUMBER OF SEQUENCES: 35
CORRESPONDENCE ADDRESS:
ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX
STREET: 1100 NEW YORK AVENUE
CITY: WASHINGTON
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/042,105
FILING DATE: HEREWITH
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/207,550
FILING DATE: 8-MAR-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/465,968
FILING DATE: 06-JUN-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: TO BE ASSIGNED
FILING DATE: 24-DEC-1997
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: ERIC K. STEFFE
REGISTRATION NUMBER: 36,688
REFERENCE/DOCKET NUMBER: 1488.1000003/EKS
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)371-2600
TELEFAX: (202)371-2540
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 419 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-042-105-2

Sequence Comparison B

SEQ ID NO: 3 amino acids 1-157

RESULT 9
Y22320
ID Y22320 standard; Protein; 419 AA.
XX
AC Y22320;
XX
DT 22-SEP-1999 (first entry)
XX
DE Full length human VEGF2 protein sequence.
XX
KW VEGF2; vascular endothelial growth factor 2; angiogenesis; bone damage;
KW endothelial cell proliferation; tissue damage; therapy.
XX
OS Homo sapiens.
XX
PN US5932540-A.
XX
PD 03-AUG-1999.
XX
PF 24-DEC-1997; 97US-0999811.
XX
PR 24-DEC-1997; 97US-0999811.
PR 08-MAR-1994; 94US-0207550.
PR 06-JUN-1995; 95US-0465968.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Cao L, Hu J, Rosen CA;
XX
DR WPI; 1999-443606/37.
DR N-PSDB; X84837.
XX
PT Vascular endothelial growth factor 2 for wound healing and vascular
PT repair
XX
PS Claim 1; Fig 1; 49pp; English.
XX
CC This sequence is the vascular endothelial growth factor 2 (VEGF2),
CC of the invention. The isolated polypeptide is useful for stimulating
CC angiogenesis, by promoting the proliferation of endothelial cells, for
CC the treatment of a wound, or for the treatment of tissue or bone damage.
XX
SQ Sequence 419 AA;

Query Match 98.4%; Score 814; DB 20; Length 419;
Best Local Similarity 98.7%; Pred. No. 6.3e-80;
Matches 155; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 MHLLGFFSVACSLLAAALLPGPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQ 60
|| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1 mhslgffsvacsllaallpgpreapaaaaafesglidlrsaepdageatayaskdleeql 60
Qy 61 RSVSSVDELMTVLYPEYWKMYKCQLRKGGWQHNREQANLNSRTEETIKFAAAHTNTEILK 120
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 61 rsvssvdelmtvlypeywkmkycqqlrkggwqhnrqanlnsreteetikfaahynteilk 120
Qy 121 SIDNEWRKTQCMPPREVCIDVGKEFGVATNTFFKPPCV 157
||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 121 sidnewrktqcmpprevcidvgkefgvatntffkppcv 157

Sequence Comparison C
SEQ ID NO: 3 amino acids 21-157

PN US5932540-A.
XX
PD 03-AUG-1999.
XX
PF 24-DEC-1997; 97US-0999811.
XX
PR 24-DEC-1997; 97US-0999811.
PR 08-MA PN US5932540-A.
XX
PD 03-AUG-1999.
XX
PF 24-DEC-1997; 97US-0999811.
XX
PR 24-DEC-1997; 97US-0999811.
PR 08-MAR-1994; 94US-0207550.
PR 06-JUN-1995; 95US-0465968.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Cao L, Hu J, Rosen CA;
XX
DR WPI; 1999-443606/37.
DR N-PSDB; X84837.
XX
PT Vascular endothelial growth factor 2 for wound healing and vascular
repair
XX
PS Claim 1; Fig 1; 49pp; English.
XX
CC This sequence is the vascular endothelial growth factor 2 (VEGF2),
CC of the invention. The isolated polypeptide is useful for stimulating
CC angiogenesis, by promoting the proliferation of endothelial cells, for
CC the treatment of a wound, or for the treatment of tissue or bone damage.
XX
SQ Sequence 419 AA;

Query Match 99.0%; Score 721; DB 20; Length 419;
Best Local Similarity 99.3%; Pred. No. 2.2e-74;
Matches 136; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMVLYPEYWKM 60
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 21 gpreapaaaaafesglrlsdaepdageatayaskdleeqlrsvssvdelmtvlypeywkm 80

Qy 61 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHTNTEILKSIDNEWRKTQCMPPREVCIDV 120
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 81 ykcqlrkggwqhnreqanlnsrteetikfaahynteilksidnewrktqcmpprevcidv 140

Qy 121 GKEFGVATNTFFKPPCV 137
||| ||| ||| ||| |||
Db 141 gkefgvatntffkppcv 157

Sequence Comparison D
SEQ ID NO: 3 amino acids 21-419

PN US5932540-A.
XX
PD 03-AUG-1999.
XX
PF 24-DEC-1997; 97US-0999811.
XX
PR 24-DEC-1997; 97US-0999811.
PR 08-MAR-1994; 94US-0207550.
PR 06-JUN-1995; 95US-0465968.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Cao L, Hu J, Rosen CA;
XX
DR WPI; 1999-443606/37.
DR N-PSDB; X84837.
XX
PT Vascular endothelial growth factor 2 for wound healing and vascular
repair
XX
PS Claim 1; Fig 1; 49pp; English.
XX
CC This sequence is the vascular endothelial growth factor 2 (VEGF2),
CC of the invention. The isolated polypeptide is useful for stimulating
CC angiogenesis, by promoting the proliferation of endothelial cells, for
CC the treatment of a wound, or for the treatment of tissue or bone damage.
XX
SQ Sequence 419 AA;

Query Match 99.5%; Score 2224; DB 20; Length 419;
Best Local Similarity 99.5%; Pred. No. 1.9e-162;
Matches 397; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMTVLYPEYWKM 60
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 21 gpreapaaaaafesglldlsdaepdageatayaskdleeqlrsvssvdelmtvlypeywkm 80

Qy 61 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHTNTTEILKSIDNEWRKTQCMPPREVCIDV 120
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 81 ykcqlrkggwqhnreqanlnsrteetikfaahynteilksidnewrktqcmpprevcidv 140

Qy 121 GKEFGVATNTFFKPPCVSVYRCGGCCNSEGLQCMNTSTSylsktlfeitvplsqqpkpvt 180
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 141 gkefgvatntffkppcvsvyrcggccnsegllqcmntstsylsktlfeitvplsqqpkpvt 200

Qy 181 ISFANHTSCRCMSKLDVYRQVHSIIIRRSLPATLPQCQAANKTCPTNYMWNNHICRCLAQE 240
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 201 isfanhtscrcmskldvyrqvhsirrslpatlpqcqaanktcptnymwnnhicrclaqe 260

Qy 241 DFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCVRAGLPRASCQPHKELDRNSCQCVCK 300
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 261 ddfmfssdagddstdgfhdicgpnkeldeetcqcvcvragslprascqphkeldrnscqcvck 320

Qy 301 NKLFPSQCGANREFDENTCQCVCKRTCPRNQPLNPGKCACECTESPQKCLLKGKKFHQT 360
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 321 nklfpsqcganrefdencqcvcrkrtcpqrnqplnpgkcacectespqkcllkgkkfhhqt 380

Qy 361 CSCYRRPCTNRQKACEPGFSYSEEVCRCPVPSYWKRPQMS 399
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 381 cscyrrpctnrqkacepgfsyseevcrccvpsywqrpqms 419

09813299

SEQ ID NO: 3 21-49

RESULT 4
W13833
ID W13833 standard; Protein; 419 AA.
XX
AC W13833;
XX
DT 05-JUN-1997 (first entry)
XX
DE Human vascular endothelial growth factor-related protein VRP.
XX
KW Vascular endothelial growth factor-related protein; VRP; VEGF;
KW receptor protein tyrosine kinase; Flt4; signal transduction;
KW wound healing; vulnery; rheumatoid arthritis; Kaposi's sarcoma;
KW therapy; diagnosis; angiogenesis; monoclonal antibody.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..20
FT /label= Sig_peptide
FT Protein 20..419
FT /label= Mat_protein
FT Misc-difference 114
FT /note= "deduced residue from nucleotide sequence
FT is tyrosine"
XX
PN WO9709427-A1.
XX
PD 13-MAR-1997.
XX
PF 30-AUG-1996; 96WO-US14075.
XX
PR 08-SEP-1995; 95US-0003491.
XX
PA (GETH) GENENTECH INC.
XX
PI Lee J, Wood W;
XX
DR WPI; 1997-192902/17.
DR N-PSDB; T59929.
XX
PT Human protein similar to vascular endothelial growth factor - used
PT to treat e.g. wounds, tumours, rheumatoid arthritis, Kaposi's
PT sarcoma etc.
XX
PS Claim 6; Fig 1A-D; 68pp; English.
XX
CC A human vascular endothelial growth factor (VEGF)-related protein
CC (VRP) (W13833) has been identified that binds to, and stimulates
CC the phosphorylation of, the receptor tyrosine kinase Flt4. It is
CC postulated to be a third member of the VEGF protein family. Its
CC amino acid sequence was deduced from a cDNA clone (T59929) obt.
CC from a glioma G61 library. Recombinant VRP can be produced in
CC transformed host cells and used: to promote growth of vascular and
CC lymph endothelial cells; to stimulate phosphorylation of the
CC tyrosine kinase domain of a Flt4 receptor; as a diagnostic; as an
CC additive to cell cultures; to screen for (ant)agonists; and to
CC raise monoclonal antibodies used to treat conditions associated
CC with excessive neovascularisation or vascular permeability. VRP
CC may make it possible to avoid coronary by-pass surgery by
CC stimulating growth of the collateral circulation.
XX
SQ Sequence 419 AA;

Query Match 100.0%; Score 145; DB 18; Length 419;
Best Local Similarity 100.0%; Pred. No. 1.2e-13;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEAT 29
Db 21 gpreapaaaafesglldlsdaepdageat 49

RESULT 1
US-08-999-811-2
; Sequence 2, Application US/08999811
; Patent No. 5932540
; GENERAL INFORMATION:
; APPLICANT: HU, JING-SHAN
; APPLICANT: ROSEN, CRAIG A.
; APPLICANT: CAO, LIANG
; TITLE OF INVENTION: VASCULAR ENDOTHELIAL GROWTH FACTOR 2
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX
; STREET: 1100 NEW YORK AVENUE
; CITY: WASHINGTON
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/999,811
; FILING DATE: HEREWITH
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/207,550
; FILING DATE: 8-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/465,968
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: MARKOWICZ, KAREN R.
; REGISTRATION NUMBER: 36,351
; REFERENCE/DOCKET NUMBER: 1488.1000004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)371-2600
; TELEFAX: (202)371-2540
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 419 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-999-811-2

Query Match 100.0%; Score 145; DB 2; Length 419;
Best Local Similarity 100.0%; Pred. No. 4.7e-14;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEAT 29
Db 21 GPREAPAAAAAFESGLDLSDAEPDAGEAT 49

SEQ ID NO: 3 1-49

RESULT 3
W17837
ID W17837 standard; Protein; 419 AA.
XX
AC W17837;

XX
DT 13-JAN-1998 (first entry)
XX
DE Human foetal liver kinase A binding protein flk-1bp.
XX
KW Foetal liver kinase 1 binding protein; human; flk-1bp;
KW receptor tyrosine kinase; vasculogenesis; angiogenesis;
KW wound healing; tumour; therapy; antagonist; antibody.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..20
FT /label= Sig_peptide
FT Protein 21..419
FT /label= Mat_protein
FT /note= "(Claim 10)"
FT Peptide 21..35
FT /label= N-terminal
FT /note= "(Claim 9)"
XX
PN WO9717442-A1.
XX
PD 15-MAY-1997.
XX
PF 05-NOV-1996; 96WO-US17584.
XX
PR 08-NOV-1995; 95US-0554374.
XX
PA (IMMV) IMMUNEX CORP.
XX
PI Lyman SD;
XX
DR WPI; 1997-281031/25.
DR N-PSDB; T68811.
XX
PT DNA encoding a human foetal liver kinase 1 binding protein - used
PT to treat conditions with insufficient protein, deliver agents to
PT cells and identify antagonists to treat protein-mediated conditions
XX
PS Claim 1; Page 30-32; 43pp; English.
XX
CC This polypeptide comprises a human foetal liver kinase 1 binding
CC protein (flk-1bp) (see W17837) that binds to the receptor tyrosine
CC kinase flk-1 expressed on vascular endothelial and other cells.
CC The mature flk1-bp can be secreted from host cells transformed with
CC an expression vector including an isolated flk-1bp cDNA clone (see
CC T68811). Flk-1bp can be used to isolate cells to which it binds,
CC for use in studying the roles of such cells and of flk-1 in
CC vasculogenesis and angiogenesis. Angiogenesis inhibition or
CC increased vascularisation may be clinically desirable (e.g. to
CC suppress solid tumour growth or in wound healing, respectively).
CC The flk-1bp can be administered to treat conditions with defective
CC or insufficient flk-1. Polypeptides may also act as carriers to
CC deliver diagnostic/therapeutic agents to cells to which flk1-bp
CC binds, to generate antibodies, and to identify flk-1bp antagonists
CC useful for treating flk-1bp mediated conditions.
XX
SQ Sequence 419 AA;

Query Match 99.0%; Score 721; DB 18; Length 419;
Best Local Similarity 99.3%; Pred. No. 2.2e-74;
Matches 136; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMVLYPEYWKM 60
Db 21 gpreapaaaaafesglidlrsaepdageatayaskdleeqlrsvssvdelmtvlypeywm 80
Qy 61 YKCQLRKGWQHNREQANLNSRTEETIKFAAAHTNTEILKSIDNEWRKTQCMPPREVCIDV 120
Db 81 ykcqlrkgwqhnreqanlnsrteetikfaaahtnnteilksidnewrktqcmpprevcidv 100

Db 81 ykcqlrkggwqhnreqanlnsrteetikfaahynteilksidnewrktqcmprevcidv 140
Qy 121 GKEFGVATNTFFKPPCV 137
|||
Db 141 gkefgvatntffkppcv 157

RESULT 8
Y22320
ID Y22320 standard; Protein; 419 AA.
XX
AC Y22320;
XX
DT 22-SEP-1999 (first entry)
XX
DE Full length human VEGF2 protein sequence.
XX
KW VEGF2; vascular endothelial growth factor 2; angiogenesis; bone damage;
KW endothelial cell proliferation; tissue damage; therapy.
XX
OS Homo sapiens.
XX
PN US5932540-A.
XX
PD 03-AUG-1999.
XX
PF 24-DEC-1997; 97US-0999811.
XX
PR 24-DEC-1997; 97US-0999811.
PR 08-MAR-1994; 94US-0207550.
PR 06-JUN-1995; 95US-0465968.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Cao L, Hu J, Rosen CA;
XX
DR WPI; 1999-443606/37.
DR N-PSDB; X84837.
XX
PT Vascular endothelial growth factor 2 for wound healing and vascular
PT repair
XX
PS Claim 1; Fig 1; 49pp; English.
XX
CC This sequence is the vascular endothelial growth factor 2 (VEGF2),
CC of the invention. The isolated polypeptide is useful for stimulating
CC angiogenesis, by promoting the proliferation of endothelial cells, for
CC the treatment of a wound, or for the treatment of tissue or bone damage.
XX
SQ Sequence 419 AA;

Query Match 99.0%; Score 721; DB 20; Length 419;
Best Local Similarity 99.3%; Pred. No. 2.2e-74;
Matches 136; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMTVLYPEYWKM 60
|||
Db 21 gpreapaaaaafesglrlsdaepdageatayaskdleeqlrsvssvdelmtvlypeywkm 80
Qy 61 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHTNTEILKSIDNEWRKTQCMPREVCIDV 120
|||
Db 81 ykcqlrkggwqhnreqanlnsrteetikfaahynteilksidnewrktqcmprevcidv 140
Qy 121 GKEFGVATNTFFKPPCV 137
|||
Db 141 gkefgvatntffkppcv 157

RESULT 1

US-08-999-811-2
; Sequence 2, Application US/08999811
; Patent No. 5932540
; GENERAL INFORMATION:
; APPLICANT: HU, JING-SHAN
; APPLICANT: ROSEN, CRAIG A.
; APPLICANT: CAO, LIANG
; TITLE OF INVENTION: VASCULAR ENDOTHELIAL GROWTH FACTOR 2
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX
; STREET: 1100 NEW YORK AVENUE
; CITY: WASHINGTON
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/999,811
; FILING DATE: HEREWITH
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/207,550
; FILING DATE: 8-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/465,968
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: MARKOWICZ, KAREN R.
; REGISTRATION NUMBER: 36,351
; REFERENCE/DOCKET NUMBER: 1488.1000004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)371-2600
; TELEFAX: (202)371-2540
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 419 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-999-811-2

Query Match 99.0%; Score 721; DB 2; Length 419;
Best Local Similarity 99.3%; Pred. No. 6.8e-80;
Matches 136; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMVLYPEYWM 60
Db 21 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMVLYPEYWM 80
Qy 61 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHTNTEILKSIDNEWRKTQCMPREVCIDV 120
Db 81 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHYNTEILKSIDNEWRKTQCMPREVCIDV 140
Qy 121 GKEFGVATNTFFKPPCV 137
Db 141 GKEFGVATNTFFKPPCV 157

SEQ ID NO: 3, 21-419

RESULT 1
US-08-795-430-8
; Sequence 8, Application US/08795430
; Patent No. 6130071

; GENERAL INFORMATION:
; APPLICANT: Alitalo, Kari
; APPLICANT: Joukov, Vladimir
; TITLE OF INVENTION: Vascular Endothelial Growth Factor C (VEGF-C)
; TITLE OF INVENTION: Protein and Gene, Mutants Thereof, and Uses Thereof
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/795,430
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/FI96/00427
; FILING DATE: 01-AUG-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/671,573
; FILING DATE: 28-JUN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/601,132
; FILING DATE: 14-FEB-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,895
; FILING DATE: 12-JAN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/510,133
; FILING DATE: 01-AUG-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/340,011
; FILING DATE: 14-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Gass, David A.
; REGISTRATION NUMBER: 38,153
; REFERENCE/DOCKET NUMBER: 28967/33691
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 419 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-795-430-8

Query Match 99.7%; Score 2228; DB 3; Length 419;
Best Local Similarity 99.7%; Pred. No. 5.5e-193;
Matches 398; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMVLYPEYWM 60
|||
Db 21 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMVLYPEYWM 80

Qy 61 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHTNTEILKSIDNEWRKTQCMPPREVCIDV 120
|||
Db 81 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHYNTEILKSIDNEWRKTQCMPPREVCIDV 140

Qy 121 GKEFGVATNTFFKPPCVSRYRCGGCCNSEGLQCMNTSTSylSKTLFEITVPLSQGPKPVT 180
|||

Db 141 GKEFGVATNTFFKPPCVSVYRCGGCNSEGLQCMNTSTSILSRTLFEITVPLSQGPVPT 200
Qy 181 ISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPTNYMWNNHICRCLAQE 240
Db 201 ISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPTNYMWNNHICRCLAQE 260
Qy 241 DFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSQCVCCK 300
Db 261 DFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSQCVCCK 320
Qy 301 NKLFPSCQGANREFDENTCQCVCKRTCPRNQPLNPGKCACECTESPQKCLLGKKFHHQT 360
Db 321 NKLFPSCQGANREFDENTCQCVCKRTCPRNQPLNPGKCACECTESPQKCLLGKKFHHQT 380
Qy 361 CSCYRRPCTNRQKACEPGFSYSEEVCRCPVSYWKRQMS 399
Db 381 CSCYRRPCTNRQKACEPGFSYSEEVCRCPVSYWKRQMS 419

RESULT 2
US-08-999-811-2
; Sequence 2, Application US/08999811
; Patent No. 5932540
; GENERAL INFORMATION:
; APPLICANT: HU, JING-SHAN
; APPLICANT: ROSEN, CRAIG A.
; APPLICANT: CAO, LIANG
; TITLE OF INVENTION: VASCULAR ENDOTHELIAL GROWTH FACTOR 2
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX
; STREET: 1100 NEW YORK AVENUE
; CITY: WASHINGTON
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/999,811
; FILING DATE: HEREWITH
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/207,550
; FILING DATE: 8-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/465,968
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: MARKOWICZ, KAREN R.
; REGISTRATION NUMBER: 36,351
; REFERENCE/DOCKET NUMBER: 1488.1000004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)371-2600
; TELEFAX: (202)371-2540
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 419 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-999-811-2

Query Match 99.5%; Score 2224; DB 2; Length 419;
Best Local Similarity 99.5%; Pred. No. 1.3e-192;
Matches 397; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMTVLYPEYWKM 60
Db 21 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMTVLYPEYWKM 80

Qy 61 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHTNTEILKSIDNEWRKTQCMPREVCIDV 120
Db 81 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHYNTEILKSIDNEWRKTQCMPREVCIDV 140

Qy 121 GKEFGVATNTFFKPPCVSVYRCGGCNSEGLQCMNTSTSylSKTLFEITVPLSQGPKPV 180
Db 141 GKEFGVATNTFFKPPCVSVYRCGGCNSEGLQCMNTSTSylSKTLFEITVPLSQGPKPV 200

Qy 181 ISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPNTNYMWNNHICRCLAQE 240
Db 201 ISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPNTNYMWNNHICRCLAQE 260

Qy 241 DFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSCQCVCK 300
Db 261 DFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSCQCVCK 320

Qy 301 NKLFPSQCGANREFDENTCQCVCKRTCPRNQPLNPGKCACECTESPQKCLLKGKKFHHQT 360
Db 321 NKLFPSQCGANREFDENTCQCVCKRTCPRNQPLNPGKCACECTESPQKCLLKGKKFHHQT 380

Qy 361 CSCYRRPCTNRQKACEPGFSYSEEVCRCPVPSYWRPQMS 399
Db 381 CSCYRRPCTNRQKACEPGFSYSEEVCRCPVPSYWRPQMS 419

RESULT 4
US-09-042-105-18
; Sequence 18, Application US/09042105
; Patent No. 6040157
; GENERAL INFORMATION:
; APPLICANT: HU, JING-SHAN
; APPLICANT: ROSEN, CRAIG A.
; APPLICANT: CAO, LIANG
; TITLE OF INVENTION: VASCULAR ENDOTHELIAL GROWTH FACTOR 2
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX
; STREET: 1100 NEW YORK AVENUE
; CITY: WASHINGTON
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/042,105
; FILING DATE: HEREWITH
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/207,550
; FILING DATE: 8-MAR-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/465,968
; FILING DATE: 06-JUN-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: TO BE ASSIGNED
; FILING DATE: 24-DEC-1997
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: ERIC K. STEFFE
; REGISTRATION NUMBER: 36,688

; REFERENCE/DOCKET NUMBER: 1488.1000003/EKS
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)371-2600
; TELEFAX: (202)371-2540
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 419 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-042-105-18

Query Match 99.5%; Score 2224; DB 3; Length 419;
Best Local Similarity 99.5%; Pred. No. 1.3e-192;
Matches 397; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMVLYPEYWMK 60
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 21 GPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMVLYPEYWMK 80
Qy 61 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHTNTEILKSIDNEWRKTQCMPREVCIDV 120
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 81 YKCQLRKGGWQHNREQANLNSRTEETIKFAAAHYNTEILKSIDNEWRKTQCMPREVCIDV 140
Qy 121 GKEFGVATNTFFKPPCVSVYRCGGCNSEGLQCMNTSTSILSKTLFEITVPLSQGPKPVT 180
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 141 GKEFGVATNTFFKPPCVSVYRCGGCNSEGLQCMNTSTSILSKTLFEITVPLSQGPKPVT 200
Qy 181 ISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPTNYMWNNHICRCLAQE 240
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 201 ISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPTNYMWNNHICRCLAQE 260
Qy 241 DFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSQCVCCK 300
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 261 DFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSQCVCCK 320
Qy 301 NKLFPSQCGANREFDENTCQCVCKRTCPRNQPLNPGKCACETESPQKCLLKGKKFHQT 360
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 321 NKLFPSQCGANREFDENTCQCVCKRTCPRNQPLNPGKCACETESPQKCLLKGKKFHQT 380
Qy 361 CSCYRRPCTNRQKACEPGFSYSEEVCRCPVSYWKRQMS 399
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 381 CSCYRRPCTNRQKACEPGFSYSEEVCRCPVSYWQRQMS 419